Bassil I. Dahiyat Sells 49,278 Shares of Xencor, Inc. (NASDAQ:XNCR) Stock

Xencor, Inc. (NASDAQ:XNCR) CEO Bassil I. Dahiyat sold 49,278 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $24.07, for a total transaction of $1,186,121.46. Following the sale, the chief executive officer now directly owns 352,615 shares in the company, valued at approximately $8,487,443.05. This represents a 12.26 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Xencor Stock Performance

XNCR stock opened at $25.30 on Wednesday. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $26.84. The business’s fifty day moving average is $21.57 and its 200-day moving average is $20.39. The company has a market cap of $1.77 billion, a P/E ratio of -8.14 and a beta of 0.66.

Xencor (NASDAQ:XNCR) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating the consensus estimate of ($0.98) by $0.27. The firm had revenue of $10.70 million for the quarter, compared to analyst estimates of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company’s quarterly revenue was down 81.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. Equities research analysts forecast that Xencor, Inc. will post -3.71 EPS for the current year.

Wall Street Analysts Forecast Growth

XNCR has been the topic of a number of research reports. BMO Capital Markets reiterated an “outperform” rating and set a $34.00 target price (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Royal Bank of Canada increased their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Wedbush restated an “outperform” rating and set a $38.00 target price on shares of Xencor in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their price target on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.75.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Primecap Management Co. CA boosted its position in shares of Xencor by 0.3% during the second quarter. Primecap Management Co. CA now owns 9,116,202 shares of the biopharmaceutical company’s stock worth $172,570,000 after purchasing an additional 25,495 shares in the last quarter. Vanguard Group Inc. raised its stake in Xencor by 3.6% during the 1st quarter. Vanguard Group Inc. now owns 7,011,042 shares of the biopharmaceutical company’s stock worth $155,154,000 after buying an additional 243,793 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in Xencor by 9.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock worth $84,530,000 after acquiring an additional 335,881 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Xencor by 147.3% in the third quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock valued at $62,748,000 after acquiring an additional 1,858,440 shares during the period. Finally, Logos Global Management LP increased its holdings in shares of Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $28,395,000 after acquiring an additional 850,000 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.